Drug intelligence / Profile preview

yy003

Development stage: Phase 2
Lead developer: Claruvis Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Injection

Overview

YY003 is the world's first liquid formulation of recombinant Botulinum Toxin Type A (rBoNT/A), packaged in a pre-filled syringe. It is a SNAP25 modulator developed by Claruvis Pharmaceutical Co. The drug is designed primarily for the treatment of moderate to severe glabellar lines (frown lines). YY003 represents an innovation in the botulinum toxin market, offering a safer and more convenient option compared to traditional powder formulations that require reconstitution.

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on yy003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yy003.

Explore the full profile